Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1184P - Improving the tolerability of osimertinib by identifying its toxic limit

Date

10 Sep 2022

Session

Poster session 16

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Bram Agema

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

B.C. Agema1, M.G.D. Veerman1, D. Lanser1, C.M.J. Steendam2, T. Preijers3, C. Van Der Leest2, B. Koch3, A.C. Dingemans4, R.H. Mathijssen1, S.L. Koolen1

Author affiliations

  • 1 Medical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 2 Pulmonology, Amphia Ziekenhuis-location Molengracht, 4818 CK - Breda/NL
  • 3 Clinical Pharmacy, Erasmus MC - Erasmus University Rotterdam, 3000 CA - Rotterdam/NL
  • 4 Pulmonology Department, Erasmus MC - University Medical Center, 3000 CA - Rotterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1184P

Background

Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible to identify patients at risk of severe toxicity beforehand. We hence aimed to study the relationship between osimertinib exposure and severe toxicity, and to identify a safe toxic limit for a preventive dose reduction.

Methods

In this real-life prospective cohort study, patients with NSCLC treated with osimertinib were followed for severe toxicity (grade ≥3 toxicity, dose reduction or discontinuation, hospital admission, or treatment termination). Blood for pharmacokinetic analyses was withdrawn during every out-patient visit. To quantify individual exposure to osimertinib, a population-pharmacokinetic model was developed. Primary endpoint was the correlation between osimertinib clearance (exposure) and severe toxicity. Secondary endpoint was the exposure-efficacy relationship, defined as progression-free (PFS) and overall survival (OS).

Results

In total, 819 samples from 159 patients were included in the analysis. Multivariate competing risk analysis showed osimertinib clearance (c.q. exposure) to be significantly correlated with severe toxicity (hazard ratio (HR) 0.93, 95% CI 0.88 – 0.99). An ROC-curve showed the optimal toxic limit to be 259 ng/mL osimertinib. This target concentration divides the cohort in two groups: the risk of severe toxicity in the >259 ng/mL group is 34% versus 14% in the <259 ng/mL group. A 50% dose reduction in the high-exposure group - i.e. 25.8% of the total cohort - would reduce the risk of severe toxicity by 53%. Correlation of the first plasma trough concentrations in collected in the first two months of treatment revealed a similar difference in severe toxicity (31% versus 17%), when dividing the cohort in two by the toxic limit of 259 ng/mL osimertinib. Osimertinib exposure was not significantly associated with PFS nor OS.

Conclusions

Osimertinib exposure is highly correlated with occurrence of severe toxicity. To optimize tolerability, patients above the toxic limit concentration of 259 ng/mL could benefit from a preventive dose reduction, without fear for diminished effectiveness.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

C. Van Der Leest: Financial Interests, Personal, Advisory Board: MSD, BMC, Roche; Financial Interests, Personal, Invited Speaker: Novartis. A.C. Dingemans: Financial Interests, Institutional, Advisory Board: Roche, Sanofi, Amgen, Bayer, Boehringer Ingelheim; Financial Interests, Institutional, Invited Speaker: Takeda, Lilly, Jansen, Pfizer, AstraZeneca, Lilly, Amgen, Daiichi, Roche, Roche, JNJ, Mirati; Financial Interests, Institutional, Research Grant: Amgen; Non-Financial Interests, Other, Chair lung cancer group; EORTC; Non-Financial Interests, Member: IASCL, ASCO, AACR. R.H. Mathijssen: Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Advisory Role: Servier; Financial Interests, Personal, Proprietary Information, Patent pending: Pamgene; Financial Interests, Institutional, Research Grant, Investigator-initiated research-initiated investigation: Astellas, Bayer; Financial Interests, Institutional, Research Grant, Investigator-initiated research: Boehringer Ingelheim, Cristal Therapeutics, Pamgene, Pfizer, Novartis, Roche, Servier. S.L. Koolen: Financial Interests, Personal, Invited Speaker: Promise Proteomics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.